Bone Mineral Density After Childhood Cancer in 346 Long-term Adult Survivors of Childhood Cancer
Overview
Orthopedics
Authors
Affiliations
Summary: More than 45 % of long-term childhood cancer survivors (CCS) were diagnosed with osteopenia. Our data suggest that greater awareness for osteopenia is warranted in long-term CCS, especially in survivors who are older than 30 years, male, and underweight and were treated with cranial-spinal radiotherapy and/or steroids.
Introduction: Osteopenia is a potential complication of childhood cancer treatment, but the magnitude of this problem in survivors is unknown. We examined (determinants of) bone mineral density (BMD) status in long-term survivors of adult childhood cancer.
Methods: This retrospective single-centre cohort study included 346 subjects with the most common types of childhood cancer. Subjects had a median age at diagnosis of 7.0 years (range 0.1-16.8 years), a median age at follow-up of 24.5 years (range 18.0-47.6 years) and a median follow-up time of 16.7 years (range 5.6-39.9 years). Total body BMD (BMDTB) and BMD of the lumbar spine (BMDLS) were measured by dual X-ray absorptiometry. Osteopenia was defined as BMD standardized deviation score (SDS) below -1.
Results: Survivors had a lower BMDTB and BMDLS (mean SDS -0.55; p<0.001 and -0.30; p<0.001, respectively) as compared to healthy peers. Osteopenia (BMDTB and/or BMDLS) was present in 45% of the survivors. Multivariate logistic regression analyses identified age at diagnosis<12 years, age>30 years at follow-up, male gender, underweight at follow-up and treatment with cranial-spinal radiotherapy or prednisone as independent prognostic factors for osteopenia.
Conclusions: This large cohort of childhood cancer survivors identified osteopenia in 45% of CCS. This indicates that greater awareness is warranted, especially in survivors who are older than 30 years, male, have underweight and were treated with cranial-spinal radiotherapy and/or steroids.
de Winter D, Neggers S, van den Heuvel-Eibrink M, van Atteveld J Endocr Connect. 2024; 13(12).
PMID: 39437150 PMC: 11623254. DOI: 10.1530/EC-24-0487.
de Beijer I, Bouwman E, Mulder R, Steensma P, Brown M, Araujo-Soares V Cancer Med. 2024; 13(12):e7361.
PMID: 39291862 PMC: 11192647. DOI: 10.1002/cam4.7361.
Bone health in childhood low-grade glioma: an understudied problem.
Van Roessel I, Gorter J, Bakker B, van den Heuvel-Eibrink M, Lequin M, van der Lugt J Endocr Connect. 2024; 13(10).
PMID: 39140359 PMC: 11466249. DOI: 10.1530/EC-24-0224.
Brunold K, Otth M, Scheinemann K Discov Oncol. 2024; 15(1):17.
PMID: 38270745 PMC: 10810765. DOI: 10.1007/s12672-024-00861-0.
Transition of young adults with metabolic bone diseases to adult care.
Ross J, Bowden M, Yu C, Diaz-Thomas A Front Endocrinol (Lausanne). 2023; 14:1137976.
PMID: 37008909 PMC: 10064010. DOI: 10.3389/fendo.2023.1137976.